Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
From the June 2013 NEJM...peer reviewed reporting on PFE's NCT00932893.
"Conclusion: Crizotinib is superior to standard chemotherapy in patients with pre-treated advanced NSCLC with ALK rearrangement (ALK +)
It appears likely that Crizotinib will replace chemo in advanced ALK+ NSCLC. Should this label expansion take place, ganetespib will likely catch a ride on Crizo's coattails with it 's known capacity to reverse Crizo-induced resistance. If the PFS translates to extended OS in the ongoing combo trial, G is a shoe-in...JMHO